Zanidatamab (zani) in previously treated HER2+ biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study. Analysis of patients (pts) with unresectable ...
Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune ...
In today's digital economy, data has become one of the most valuable assets any organization can possess. Yet, for all its abundance, data on its own rarely leads to understanding. The challenge for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results